UNSPSC 51111703: Daunorubicin citrate

This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5L84T2Z6NP. European Medicines Agency schedules daunorubicin citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22734. The term daunorubicin citrate is a U.S. FDA designation. Most nations schedule daunorubicin citrate under HS 29419000 and SITC 54139. As of Q4 2014, DAUNORUBICIN CITRATE remains the US FDA Preferred Term for this commodity.

Daunorubicin citrate bears US NLM identifiers UMLS ID C1289972 and NCI Concept Code C47471. SMILES: CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51111703 Daunorubicin citrate is a Commodity code for a specific cytotoxic chemotherapy agent used in acute leukemia and lymphoma treatments. State and local governments procure this pharmaceutical under pharmacy benefit programs, government employee health plans, and public health agency formularies, typically through established drug distribution channels, group purchasing organizations, or direct manufacturer relationships. The Texas Health and Human Services Commission's recent activity under related pharmaceutical procurement demonstrates that state health agencies are exploring direct-to-manufacturer models to manage prescription costs and improve fulfillment efficiency, signaling potential shifts in how states source specialty pharmaceuticals like daunorubicin citrate away from traditional pharmacy benefit managers and wholesalers.

The code shows minimal recent targeted activity. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which addresses the broader pharmaceutical sourcing infrastructure rather than procurement of the drug itself. This exploratory solicitation reflects state interest in restructuring pharmacy benefit delivery and cost management but does not constitute a direct solicitation for daunorubicin citrate supply. The RFI is preliminary market intelligence, with no award values, budget allocations, or binding timelines specified at this stage. Texas HHS Commission is the primary issuing body identified in recent activity; no repeat buyers or multi-jurisdictional opportunities emerged from the available record. Geographic activity is limited to Texas. Business development professionals should monitor Texas HHS Commission and other state Medicaid and employee health plan offices for formal RFPs on specialty pharmaceutical sourcing as this exploratory phase concludes.